Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial

BACKGROUND: Mesenchymal stromal cells (MSCs) may be of benefit in ARDS due to immunomodulatory and reparative properties. This trial investigates a novel CD362 enriched umbilical cord derived MSC product (REALIST ORBCEL-C), produced to Good Manufacturing Practice standards, in patients with moderate...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorman, Ellen, Shankar-Hari, Manu, Hopkins, Phil, Tunnicliffe, William S., Perkins, Gavin D., Silversides, Jonathan, McGuigan, Peter, Jackson, Colette, Boyle, Roisin, McFerran, Jamie, McDowell, Cliona, Campbell, Christina, McFarland, Margaret, Smythe, Jon, Thompson, Jacqui, Williams, Barry, Curley, Gerard, Laffey, John G., Clarke, Mike, McAuley, Daniel F., O’Kane, Cecilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099345/
https://www.ncbi.nlm.nih.gov/pubmed/35562778
http://dx.doi.org/10.1186/s13063-022-06220-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099345/
https://www.ncbi.nlm.nih.gov/pubmed/35562778
http://dx.doi.org/10.1186/s13063-022-06220-0

Ejemplares similares